α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  He, Lizhi ^a,b   Fan, Catherine ^a,b   Kapoor, Anil ^a,b   Ingram, Alistair J ^a,b   Rybak, Adrian P ^a,b   Austin, Richard C ^a,b   Dickhout, Jeffery ^a,b   Cutz, Jean Claude ^a   Scholey, James ^c   Tang, Damu ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA MANNOSIDASE; ALPHA MANNOSIDASE 2C1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE; PTEN PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; AGED; ANIMAL; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENETICS; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

AGED; ALPHA-MANNOSIDASE; ANIMALS; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL PHOSPHATES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 79955816876     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1309     Document Type: Article

References (57)

1. Myers, M. P. et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specifcity phosphatase. Proc. Natl Acad. Sci. USA 94, 9052-9057 (1997).
2. Myers, M. P. et al. Telipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 95, 13513-13518 (1998). (Pubitemid 28523003)
3. Maehama, T. & Dixon, J. E. Tetumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375-13378 (1998). (Pubitemid 28268370)
4. Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240-4245 (1999). (Pubitemid 29190320)
5. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer; variations on a theme. Oncogene 27, 5497-5510 (2008).
6. Knobbe, C. B., Lapin, V., Suzuki, A. & Mak, T. W. Teroles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27, 5398-5415 (2008).
7. Yanagi, S. et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J. Clin. Invest. 117, 2929-2940 (2007). (Pubitemid 47529623)
8. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prosta Tecancer. Science 275, 1943-1947 (1997). (Pubitemid 27148818)
9. Steck, P. A. et al. Identifcation of a candida Tetumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362 (1997). (Pubitemid 27147102)
10. Li, D. M. & Sun, H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl Acad. Sci. USA 95, 15406-15411 (1998). (Pubitemid 29018711)
11. Bastola, D. R., Pahwa, G. S., Lin, M. F. & Cheng, P. W. Downregulation of PTEN/MMAC/TEP1 expression in human prosta Tecancer cell line DU145 by growth stimuli. Mol. Cell. Biochem. 236, 75-81 (2002). (Pubitemid 34846136)
12. Di Cristofano, A. & Pandolf, P. P. Temultiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000).
13. Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323-334 (1999).
14. Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64-67 (1997). (Pubitemid 27198157)
15. Mallory, S. B. Cowden syndrome (multiple hamartoma syndrome). Dermatol. Clin. 13, 27-31 (1995).
16. Goel, A. et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatelli Teinstability-high sporadic colorectal cancers. Cancer Res. 64, 3014-3021 (2004). (Pubitemid 38581399)
17. Whang, Y E. et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prosta Tecancer through loss of expression. Proc. Natl Acad. Sci. USA 95, 5246-5250 (1998). (Pubitemid 28208583)
18. Abate-Shen, C. & Shen, M. M. Molecular genetics of prosta Tecancer. Genes Dev. 14, 2410-2434 (2000).
19. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolf, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355 (1998). (Pubitemid 28357906)
20. Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563-1568 (1999). (Pubitemid 29098491)
21. Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/ - mice. Proc. Natl Acad. Sci. USA 98, 10320-10325 (2001). (Pubitemid 32803018)
22. Chen, M. L. et al. Tedefciency of Akt1 is sufcient to suppress tumor development in Pten+/ - mice. Genes Dev. 20, 1569-1574 (2006).
23. Freeman, D. et al. Genetic background controls tumor development in PTEN-defcient mice. Cancer Res. 66, 6492-6496 (2006). (Pubitemid 44085602)
24. Wang, S. et al. Prostate-specifc deletion of the murine Pten tumor suppressor gene leads to metastatic prosta Tecancer. Cancer Cell 4, 209-221 (2003). (Pubitemid 37163835)
25. Wu, X., Senechal, K., Neshat, M. S., Whang, Y E. & Sawyers, C. L. TePTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 95, 15587-15591 (1998). (Pubitemid 29018743)
26. Shen, M. M. & Abate-Shen, C. Pten inactivation and the emergence of androgen-independent prosta Tecancer. Cancer Res. 67, 6535-6538 (2007). (Pubitemid 47105495)
27. Kumar, R. et al. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prosta Tecancer cells. Cancer Prev. Res. 2, 234-243 (2009).
28. He, L. et al. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim. Biophys. Acta 1772, 1134-1142 (2007). (Pubitemid 350184271)
29. Silva, A. et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 118, 3762-3774 (2008).
30. Cotter, L. et al. Dlg1-PTEN interaction regulates myelin thickness to prevent damaging peripheral nerve overmyelination. Science 328, 1415-1418 (2010).
31. Fine, B. et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325, 1261-1265 (2009).
32. He, L., Ingram, A., Rybak, A. P. & Tang, D. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J. Clin. Invest. 120, 2094-2108 (2010).
33. Li, B. et al. Cloning, expression and characterization of a cDNA (6A8) encoding a novel human alpha-mannosidase. Eur. J. Biochem. 267, 7176-7183 (2000).
34. Roth, J., Zuber, C, Guhl, B., Fan, J. Y & Ziak, M. Teimportance of trimming reactions on asparagine-linked oligosaccharides for protein quality control. Histochem. Cell Biol 117, 159-169 (2002). (Pubitemid 34185622)
35. Shi, G. X., Wang, Y, Liu, Y, Cui, W, Zhao, F. T. & Zhu, L. P. Long-term expression of a transferred gene in Epstein-Barr virus transformed human B cells. Scand. J. Immunol 54, 265-272 (2001). (Pubitemid 34205738)
36. Yue, W et al. Suppression of 6A8 alpha-mannosidase gene expression reduced the potentiality of growth and metastasis of human nasopharyngeal carcinoma. Int. J. Cancer. 108, 189-195 (2004). (Pubitemid 37541769)
37. Robertson, G. P. et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl Acad. Sci. USA 95, 9418-9423 (1998). (Pubitemid 28506246)
38. Furnari, F. B., Huang, H. J. & Cavenee, W. K. Tephosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58, 5002-5008 (1998). (Pubitemid 28521148)
39. Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N. & Narayan, P. Establishment and characterization of an immortalized but non-transformed human prostaTeepithelial cell line: BPH-1. In vitro Cell Dev BiolAnim. 31, 14-24 (1995).
40. Wang, Y. et al. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res. 61, 6064-72 (2001). (Pubitemid 32762541)
41. Ao, M., Williams, K., Bhowmick, N. A. & Hayward, S. W Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 66, 8007-8016 (2006). (Pubitemid 44299165)
42. Junttila, M. R. et al. CIP2A inhibits PP2A in human malignancies. Cell 130, 51-62 (2007). (Pubitemid 47039258)
43. Pelham, H. R. Teretention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci. 15, 483-486 (1990).
44. Kim, R. H. et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263-273 (2005). (Pubitemid 40568685)
45. Guha, M., Plescia, J., Leav, I., Li, J., Languino, L. R. & Altieri, D. C. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 69, 4954-4958 (2009).
46. Xiang, Z. G., Jiang, D. D., Liu, Y., Zhang, L. F. & Zhu, L. P. hMan2c1 transgene promotes tumor progress in mice. Transgenic Res. 19, 67-75 (2010).
47. Reddy, R. K. et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding siTein suppression of caspase-7 activation. J. Biol. Chem. 278, 20915-20924 (2003). (Pubitemid 36806399)
48. Reis, C. A., Osorio, H., Silva, L., Gomes, C. & David, L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 63, 322-329 (2010).
49. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178 (1998). (Pubitemid 28494715)
50. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 (1998). (Pubitemid 28458022)
51. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G. & Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8, 1195-1198 (1998). (Pubitemid 28494720)
52. Cully, M., You, H., Levine, A. J. & Mak, T. W Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192 (2006). (Pubitemid 43292562)
53. Tang, D. et al. Akt is activated in response to an apoptotic signal. J. Biol. Chem. 276, 30461-30466 (2001).
54. Tang, X., Powelka, A. M., Soriano, N. A., Czech, M. P. & Guilherme, A. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J. Biol. Chem. 280, 22523-22529 (2005). (Pubitemid 40827910)
55. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998). (Pubitemid 28471781)
56. Georgescu, M. M., Kirsch, K. H., Akagi, T., Shishido, T. & Hanafusa, H. Tetumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl Acad. Sci. USA 96, 10182-10187 (1999). (Pubitemid 29422533)
57. Veltri, R. W et al. Prediction of prostate-specifc antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol. Biomarkers Prev. 17, 102-110 (2008). (Pubitemid 351196279)